^
Chr del(5q)
MDS
lenalidomide
Sensitive: A1 - Approval
Chr del(5q)
AML
venetoclax + ruxolitinib
Resistant: C3 – Early Trials
Chr del(5q)
AML
cytarabine + decitabine + mitoxantrone
Sensitive: C3 – Early Trials